@article{954a7db9b8e444d79223e8f8bc211e5f,
title = "Does MDS-UPDRS Provide Greater Sensitivity to Mild Disease than UPDRS in De Novo Parkinson's Disease?",
abstract = "Background: The Movement Disorder Society revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) was designed to be more sensitive to mild motor severity than the Unified Parkinson's Disease Rating Scale (UPDRS). Objective: To test whether MDS-UPDRS Part III items provide increased sensitivity to mild motor severity when compared to the same items of the UPDRS in de novo PD patients. Method: Using a sample of 129 de novo PD patients assessed at one time point simultaneously with both scales, we compared the scale's scores on the 17 items measuring the same motor function. The scaling anchors for the MDS-UPDRS were Slight, Mild, Moderate and Severe, and for the UPDRS were Mild, Moderate, Severe and Marked. Using Classical Test Theory (CTT) we compared the distributions of the scaling anchors from the individual items. Using Item Response Theory (IRT), we examined the sensitivity of the scaling anchors from each scale to the latent-trait measurement of overall parkinsonian motor severity. Results: There was 2193 observations of individual scaling anchors from the 17 items in both scales. The CTT approach revealed frequent floor effects with only the item assessing Gait demonstrating a significance difference in the scaling distribution between the scales (P = 0.005). The IRT analyses revealed similar levels of sensitivity to the latent trait of PD motor function. Conclusion: These results do not support increased sensitivity of MDS-UPDRS over the UPDRS for assessing mild motor severity in de novo PD patients, with significant difference in the scaling only for the item assessing gait.",
keywords = "Parkinson's disease, clinimetrics, outcome measures, severity of illness index",
author = "{the SPARX Study Group} and Tosin, {Michelle H.S.} and Stebbins, {Glenn T.} and Cynthia Comella and Patterson, {Charity G.} and Hall, {Deborah A.} and Schenkman, {Margaret L.} and Kohrt, {Wendy M.} and Anthony Delitto and Josbeno, {Deborah A.} and Christiansen, {Cory L.} and Berman, {Brian D.} and Kluger, {Benzi M.} and Melanson, {Edward L.} and Samay Jain and Robichaud, {Julie A.} and Cynthia Poon and Corcos, {Daniel M.}",
note = "Funding Information: MHST: Received compensation from the Section of Movement Disorders at Rush University Medical Center from contactor/consultant services associated with the project “Secondary analysis of the SPARX dataset.” GTS: Reports consulting and advisory board membership with honoraria from: Acadia, Pharmaceuticals, Adamas Pharmaceuticals, Inc., Biogen, Inc., Ceregene, Inc., CHDI Management, Inc., Cleveland Clinic Foundation, Ingenix Pharmaceutical Services (i3 Research), MedGenesis Therapeutix, Inc., Neurocrine Biosciences, Inc., Pfizer, Inc., Tools‐4‐Patients, Ultragenyx, Inc., and the Sunshine Care Foundation. GTS received grants and research from: National Institutes of Health, Department of Defense, Michael J. Fox Foundation for Parkinson's Research, Dystonia Coalition, CHDI, Cleveland Clinic Foundation, International Parkinson and Movement Disorder Society, and CBD Solutions. GTS reports honoraria from: International Parkinson and Movement Disorder Society, American Academy of Neurology, Michael J. Fox Foundation for Parkinson's Research, Food and Drug Administration, National Institutes of Health, and the Alzheimer's Association. GTS received salary from Rush University Medical Center. CC: Serves on the editorial board of Clinical Neuropharmacology and Sleep Medicine. She receives compensation/honoraria for services as a consultant or an advisory committee member: Acorda Therapeutics, Allergan, Inc; Lundbeck Ltd.; Merz Pharmaceuticals;Acadia Pharmaceuticals; Ipsen Pharmaceuticals, Jazz Pharmaceuticals, Neurocrine Biosciences Inc., Revance Therapeutic, Sunovion., EON Biopharma. She receives royalties from Cambridge, Wolters Kluwer. CGP: Receive research funding from National Institutes of Health, Patient Centered Outcomes Research Institute, and the Department of Defense. DAH: Research support from the Parkinson's Foundation, CHDI, Michael J. Fox Foundation, Anti‐Aging Foundation, Uniqure, Biohaven, Neurocrine, Fujifilm; Editorial support from the American Academy of Neurology. Publisher Copyright: {\textcopyright} 2021 International Parkinson and Movement Disorder Society",
year = "2021",
month = oct,
doi = "10.1002/mdc3.13329",
language = "English (US)",
volume = "8",
pages = "1092--1099",
journal = "Movement Disorders Clinical Practice",
issn = "2330-1619",
publisher = "John Wiley and Sons Ltd",
number = "7",
}